Published in Lancet Oncol on November 18, 2010
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell (2012) 2.51
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol (2012) 2.09
A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol (2012) 1.94
Molecular pathogenesis of mantle cell lymphoma. J Clin Invest (2012) 1.92
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci (2011) 1.75
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood (2013) 1.72
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res (2012) 1.70
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci U S A (2013) 1.53
Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood (2014) 1.53
Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol (2015) 1.43
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 1.42
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol (2012) 1.30
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med (2011) 1.27
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
BH3-only proteins in apoptosis at a glance. J Cell Sci (2012) 1.23
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett (2014) 1.23
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia (2014) 1.16
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol (2015) 1.14
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis (2012) 1.14
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol (2011) 1.08
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood (2013) 1.07
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem (2012) 1.04
Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ (2014) 1.03
Management of indolent lymphoma: where are we now and where are we going. Blood Rev (2012) 1.02
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res (2013) 1.01
Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. PLoS One (2013) 1.00
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem (2013) 1.00
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res (2012) 0.98
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia (2014) 0.98
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis (2013) 0.94
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget (2014) 0.94
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget (2015) 0.93
ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis (2012) 0.93
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.93
New molecular targets in mantle cell lymphoma. Semin Cancer Biol (2011) 0.92
Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs (2013) 0.92
Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis. J Exp Clin Cancer Res (2013) 0.91
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid (2013) 0.91
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res (2014) 0.91
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. Cancer Res (2015) 0.91
BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One (2014) 0.91
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.91
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia (2013) 0.90
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J (2015) 0.90
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget (2015) 0.90
Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol (2011) 0.90
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget (2014) 0.89
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett (2014) 0.89
Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. Cell Death Dis (2012) 0.89
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis (2014) 0.89
Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Mol Cancer Ther (2013) 0.89
Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front Oncol (2013) 0.89
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol (2012) 0.88
The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death Dis (2012) 0.88
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol (2015) 0.88
Molecular targeted approaches in mantle cell lymphoma. Semin Hematol (2011) 0.88
Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. J Med Chem (2015) 0.87
Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. EMBO Mol Med (2012) 0.86
Manipulating the apoptotic pathway: potential therapeutics for cancer patients. Br J Clin Pharmacol (2013) 0.86
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res (2012) 0.86
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol (2014) 0.86
Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J (2015) 0.86
BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia (2014) 0.85
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res (2011) 0.85
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One (2014) 0.85
Rational development of a cytotoxic peptide to trigger cell death. Mol Pharm (2012) 0.84
Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev (2014) 0.84
Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry. PLoS One (2012) 0.83
Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood (2012) 0.83
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol (2013) 0.83
Finally, An Apoptosis-Targeting Therapeutic for Cancer. Cancer Res (2016) 0.83
Do mantle cell lymphomas have an 'Achilles heel'? Curr Opin Hematol (2014) 0.82
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J (2015) 0.82
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol (2017) 0.81
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov (2017) 0.81
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. Cell Death Dis (2014) 0.81
Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma. Clin Cancer Res (2011) 0.81
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget (2015) 0.81
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol (2013) 0.81
Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PLoS One (2015) 0.81
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death Dis (2014) 0.81
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget (2014) 0.81
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma (2013) 0.81
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene (2015) 0.80
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. Ann Oncol (2015) 0.80
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget (2016) 0.80
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Cell death: critical control points. Cell (2004) 22.56
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (1984) 8.80
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell (1989) 6.66
The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science (1985) 6.63
Programmed anuclear cell death delimits platelet life span. Cell (2007) 5.98
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol (1991) 4.89
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ (2009) 3.94
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 3.85
Mechanisms of apoptosis. Am J Pathol (2000) 3.23
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol (2001) 3.03
Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci U S A (2008) 2.67
Bcl-2 family proteins are essential for platelet survival. Cell Death Differ (2007) 2.67
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem (2003) 2.64
The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med (1993) 2.50
Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ (2009) 2.40
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J (1994) 2.16
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Essential role for the BH3-only protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte survival. Blood (2002) 1.91
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Apoptosis. Mitochondria--the death signal integrators. Science (2000) 1.81
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 1.52
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood (1992) 1.16
Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park) (2004) 1.15
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett (2010) 1.02
Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. J Med Chem (2008) 0.95
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res (2000) 0.92
Apoptosis and cell death. Foreword. Oncogene (2008) 0.82
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med (2008) 4.04
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Oncology (Williston Park) (2014) 2.77
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol (2005) 2.69
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma (2014) 2.40
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol (2003) 2.29
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol (2010) 2.20
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem (2003) 2.18
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res (2009) 2.17
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther (2005) 2.15
Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park) (2009) 2.12
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med (2002) 2.12
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 2.10
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med (2015) 2.10
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem (2007) 2.09
Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park) (2010) 2.09
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 2.09
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) (2009) 2.06
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol (2007) 2.05
Pentacam HR criteria for curvature change in keratoconus and postoperative LASIK ectasia. J Refract Surg (2012) 2.05
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.05
Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer (2013) 1.98
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.96
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr (2007) 1.84
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma (2010) 1.78
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr (2006) 1.76
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol (2006) 1.69
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood (2012) 1.67
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 1.67
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med (2010) 1.62
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2011) 1.62
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood (2013) 1.59
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood (2005) 1.59